4
Changes in Ownership
Axsome Therapeutics, Inc. Filed Acc 0001193125-26-340688
Chief Executive Officer sold 49,664 shares at an average $212.19 ($10,538,305)
- Chief Executive Officer acquired 49,664 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Table I: Non-derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| TABUTEAU HERRIOT Chief Executive Officer | 2026-08-05 | Option exercise 10b5-1 | +45,004 | $4.95 | $222,770 | 52,233 | D: show line 1 in the form |
| TABUTEAU HERRIOT Chief Executive Officer | 2026-08-05 | Sale 10b5-1 | −45,004 | $212.01 | $9,541,298 | 7,229 | D: show line 2 in the form |
| TABUTEAU HERRIOT Chief Executive Officer | 2026-08-06 | Option exercise 10b5-1 | +4,660 | $4.95 | $23,067 | 11,889 | D: show line 3 in the form |
| TABUTEAU HERRIOT Chief Executive Officer | 2026-08-06 | Sale 10b5-1 | −4,660 | $213.95 | $997,007 | 7,229 | D: show line 4 in the form |
| Open-market sales · 49,664 sh · avg $212.19 · $10,538,305 | |||||||
Table II: Derivative
| Insider | Date | Transaction | Shares | Price | Value | Exercise | Expires | Underlying | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|
| TABUTEAU HERRIOT Chief Executive Officer | 2026-08-05 | Option exercise · Stock Option (Right to Buy) 10b5-1 | −45,004 | 4,660 | D: show line 5 in the form | |||||
| TABUTEAU HERRIOT Chief Executive Officer | 2026-08-06 | Option exercise · Stock Option (Right to Buy) 10b5-1 | −4,660 | 0 | D: show line 6 in the form |
Loading xslF345X06/ownership.xml…